Caredx to report third quarter 2022 financial results

South san francisco, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on thursday, november 3, 2022. company management will host a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time. individuals interested in listening to the conference call may do so by dialing 1-800-289-0438 for domestic callers or 1-323-794-2423 for international callers. please reference conference id: 2768596. to listen to a live webcast, please visit the investor relations section of caredx’s website at: investors.caredxinc.com. about caredx – the transplant company caredx, inc., headquartered in south san francisco, california, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. caredx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. for more information, please visit: www.caredx.com.
CDNA Ratings Summary
CDNA Quant Ranking